TY - JOUR AU - Liu, Suyu AU - Lee, J. Jack PY - 2015 TI - An overview of the design and conduct of the BATTLE trials JF - Chinese Clinical Oncology; Vol 4, No 3 (September 25, 2015): Chinese Clinical Oncology (Clinical Trials in the Genome Era—Study Designs and Endpoints, Practical Considerations - Guest Editors: Daniel Sargent, Sumithra Mandrekar and Axel Grothey) Y2 - 2015 KW - N2 - Our increasing knowledge of biomedicine and genomics for human malignancies has placed us within reach of achieving personalized cancer medicine. The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE)-1 trial was the first completed, prospective biopsy-mandated, biomarker-based, adaptive randomized clinical trial for patients with advanced non-small cell lung cancer (NSCLC). The ongoing BATTLE-2 trial continues to search for effective targeted therapies by further refining the clinical trial design. The BATTLE program has demonstrated the feasibility and promise of novel biomarker-based clinical trial platforms, which has moved us one step closer to personalized medicine. In this paper, we describe the design and conduct of the BATTLE trials, summarize the main findings, and report the experiences and lessons learned from our pursuit of developing targeted therapies in cancer. UR - https://cco.amegroups.org/article/view/6846